 |
40 Products |  |
109 Diseases | | 40 Products |
|
37 Trials |  |
1902 News |  |
| «12...891011121314151617181920» |
- ||||| ZemiStatin (gemigliptin/rosuvastatin FDC) / LG Chem
Enrollment closed, Trial primary completion date, Combination therapy: Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE) (clinicaltrials.gov) - Sep 15, 2015
P3, N=290, Active, not recruiting, Sponsor: LG Life Sciences
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Mar 2016
- | Eutropin Plus (somatropin SR) / LG Chem, Bioton
Trial completion, Trial primary completion date: Efficacy and Safety Study of Sr-hGH in Comparison With Daily hGH in ISS Patients (clinicaltrials.gov) - Sep 15, 2015
P2, N=46, Completed, Sponsor: LG Life Sciences
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Mar 2016 Recruiting --> Completed | Trial primary completion date: Oct 2014 --> Jul 2015
- Shinbaro (GCSB-5) / GC Pharma, LG Chem
Enrollment open: Effects of Shinbaro Pharmacopuncture in Sciatic Pain Patients With Lumbar Disc Herniation (clinicaltrials.gov) - Sep 14, 2015
P=N/A, N=60, Recruiting, Sponsor: Jaseng Medical Foundation
Recruiting --> Completed | Trial primary completion date: Oct 2014 --> Jul 2015 Not yet recruiting --> Recruiting
- ||||||| Gemiglo (gemigliptin) / Sanofi, LG Chem
Trial completion, Enrollment change, Trial primary completion date: Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin (clinicaltrials.gov) - Sep 10, 2015
P3, N=219, Completed, Sponsor: LG Life Sciences
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=174 --> 219 | Trial primary completion date: Aug 2015 --> Apr 2015
- Shinbaro (GCSB-5) / GC Pharma, LG Chem
Trial initiation date: Effects of Shinbaro Pharmacopuncture in Sciatic Pain Patients With Lumbar Disc Herniation (clinicaltrials.gov) - Aug 14, 2015
P=N/A, N=60, Not yet recruiting, Sponsor: Jaseng Medical Foundation
Active, not recruiting --> Completed | N=174 --> 219 | Trial primary completion date: Aug 2015 --> Apr 2015 Initiation date: May 2015 --> Sep 2015
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Enrollment change, Trial termination, Trial primary completion date: Tivozanib As Maintenance Therapy In GYN (clinicaltrials.gov) - Aug 11, 2015
P2, N=4, Terminated, Sponsor: Dana-Farber Cancer Institute
Initiation date: May 2015 --> Sep 2015 N=60 --> 4 | Recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Jul 2015; due to slow accrual
- Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem, Sandoz
New P1 trial: PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes (clinicaltrials.gov) - Jul 23, 2015
P1, N=40, Not yet recruiting, Sponsor: Gan and Lee Pharmaceuticals
- ||||| Gemiglo (gemigliptin) / Sanofi, LG Chem
New P4 trial: Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients (clinicaltrials.gov) - Jul 16, 2015
P4, N=54, Recruiting, Sponsor: Seoul National University Hospital
- Euvax B (recombinant hepatitis B vaccine) / LG Chem, Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi
Trial primary completion date: Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine (clinicaltrials.gov) - Jul 9, 2015
P1, N=350, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=60 --> 4 | Recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Jul 2015; due to slow accrual Trial primary completion date: Jun 2015 --> Jun 2016
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial primary completion date: Tivozanib for Recurrent Glioblastoma (clinicaltrials.gov) - Jul 9, 2015
P2, N=21, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Jun 2015 --> Jun 2016 Trial primary completion date: Jun 2015 --> Sep 2015
- || Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz
Enrollment closed, Trial primary completion date: A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols (clinicaltrials.gov) - Jun 23, 2015
P=N/A, N=200, Active, not recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
Trial primary completion date: Jun 2015 --> Sep 2015 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Jun 2013 --> Dec 2015
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Enrollment change, Combination therapy, IO biomarker, Metastases: BATON-BC: Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Jun 23, 2015
P2, N=30, Terminated, Sponsor: AVEO Pharmaceuticals, Inc.
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Jun 2013 --> Dec 2015 N=147 --> 30
- ||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Enrollment change, Metastases: TAURUS: A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC (clinicaltrials.gov) - Jun 23, 2015
P2, N=58, Completed, Sponsor: AVEO Pharmaceuticals, Inc.
N=147 --> 30 N=160 --> 58
- ||||||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial completion, P3 data: An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301). (clinicaltrials.gov) - Jun 23, 2015
P3, N=350, Completed, Sponsor: AVEO Pharmaceuticals, Inc.
N=160 --> 58 Active, not recruiting --> Completed
- Euvax B (recombinant hepatitis B vaccine) / LG Chem
Trial initiation date, Trial primary completion date: Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda (clinicaltrials.gov) - Jun 17, 2015
P4, N=132, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Initiation date: Jan 2015 --> Aug 2015 | Trial primary completion date: Jun 2016 --> Feb 2017
- ||| Adalimumab BS MA (adalimumab biosimilar) / Mochida, LG Chem
Trial completion: Pharmacokinetics and Safety Study of LBAL in Healthy Subjects (clinicaltrials.gov) - Jun 15, 2015
P1, N=116, Completed, Sponsor: LG Life Sciences
Initiation date: Jan 2015 --> Aug 2015 | Trial primary completion date: Jun 2016 --> Feb 2017 Not yet recruiting --> Completed
- Xtandi (enzalutamide capsule) / Pfizer, Astellas, Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial primary completion date, Metastases: Tivozanib + Enzalutamide in Adv Prostate Cancer (clinicaltrials.gov) - Apr 19, 2015
P2, N=42, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- Euvax B (recombinant hepatitis B vaccine) / LG Chem, Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi
Trial primary completion date: Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine (clinicaltrials.gov) - Apr 14, 2015
P1, N=350, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Mar 2015 --> Jun 2015
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial primary completion date: Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) - Apr 14, 2015
P2, N=30, Recruiting, Sponsor: Northwestern University
Trial primary completion date: Mar 2015 --> Jun 2015 Trial primary completion date: Mar 2015 --> Mar 2016
- | AV-203 / LG Chem
Trial completion, Enrollment change, Trial primary completion date, Metastases: A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Apr 8, 2015
P1, N=24, Completed, Sponsor: AVEO Pharmaceuticals, Inc.
Trial primary completion date: Mar 2015 --> Mar 2016 Active, not recruiting --> Completed | N=90 --> 24 | Trial primary completion date: May 2014 --> Dec 2014
- |||| ficlatuzumab (AV-299) / LG Chem
Trial completion, Trial primary completion date, Combination therapy: A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Apr 8, 2015
P1/2, N=203, Completed, Sponsor: AVEO Pharmaceuticals, Inc.
Active, not recruiting --> Completed | N=90 --> 24 | Trial primary completion date: May 2014 --> Dec 2014 Active, not recruiting --> Completed | Trial primary completion date: Apr 2013 --> Aug 2013
- |||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial completion, Trial primary completion date, Combination therapy, Metastases: A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy (clinicaltrials.gov) - Apr 3, 2015
P2, N=265, Completed, Sponsor: Astellas Pharma Inc
Active, not recruiting --> Completed | Trial primary completion date: Apr 2013 --> Aug 2013 Active, not recruiting --> Completed | Trial primary completion date: Feb 2014 --> Sep 2013
- |||| Gemiglo (gemigliptin) / Sanofi, LG Chem
Phase classification, Trial primary completion date: A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study) (clinicaltrials.gov) - Mar 14, 2015
P3, N=148, Recruiting, Sponsor: LG Life Sciences
Active, not recruiting --> Completed | Trial primary completion date: Feb 2014 --> Sep 2013 Phase classification: P4 --> P3 | Trial primary completion date: Jul 2014 --> Dec 2015
- Shinbaro (GCSB-5) / GC Pharma, LG Chem
Clinical: Effects of Shinbaro Pharmacopuncture in Sciatic Pain Patients With Lumbar Disc Herniation (clinicaltrials.gov) - Mar 10, 2015
P=N/A, N=60, Not yet recruiting, Sponsor: Jaseng Medical Foundation
- ficlatuzumab (AV-299) / LG Chem
Enrollment open, Trial initiation date, Trial primary completion date: Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML (clinicaltrials.gov) - Mar 9, 2015
P1, N=24, Recruiting, Sponsor: C. Babis Andreadis
Phase classification: P4 --> P3 | Trial primary completion date: Jul 2014 --> Dec 2015 Active, not recruiting --> Recruiting | Initiation date: Jan 2014 --> Jan 2015 | Trial primary completion date: Jun 2016 --> Jun 2017
- |||||| TNFcept (etanercept biosimilar) / LG Chem, Mochida
Enrollment open: A Study Comparing LBEC0101 to Enbrel (clinicaltrials.gov) - Mar 8, 2015
P3, N=372, Recruiting, Sponsor: LG Life Sciences
Active, not recruiting --> Recruiting | Initiation date: Jan 2014 --> Jan 2015 | Trial primary completion date: Jun 2016 --> Jun 2017 Not yet recruiting --> Recruiting
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial termination, Trial primary completion date, Metastases: Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer (clinicaltrials.gov) - Mar 5, 2015
P2, N=7, Terminated, Sponsor: Emory University
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated | Trial primary completion date: Jan 2016 --> Feb 2015; Primary endpoint not met
- |||||||||| TNFcept (etanercept biosimilar) / LG Chem, Mochida
New P3 trial: A Study Comparing LBEC0101 to Enbrel (clinicaltrials.gov) - Feb 6, 2015
P3, N=372, Not yet recruiting, Sponsor: LG Life Sciences
- Euvax B (recombinant hepatitis B vaccine) / LG Chem, Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi
Phase classification, Trial primary completion date: Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine (clinicaltrials.gov) - Jan 28, 2015
P1, N=350, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Terminated | Trial primary completion date: Jan 2016 --> Feb 2015; Primary endpoint not met Phase classification: P1/2 --> P1 | Trial primary completion date: Oct 2015 --> Mar 2015
- |||||||||| Gemiglo (gemigliptin) / Sanofi, LG Chem
New P3 trial: Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin (clinicaltrials.gov) - Jan 22, 2015
P3, N=440, Recruiting, Sponsor: Sanofi
- |||| Shinbaro (GCSB-5) / GC Pharma, LG Chem
Trial primary completion date: Efficacy of Shinabro in Hand Osteoarthritis (clinicaltrials.gov) - Dec 30, 2014
P2/3, N=220, Recruiting, Sponsor: Seoul National University Hospital
Phase classification: P1/2 --> P1 | Trial primary completion date: Oct 2015 --> Mar 2015 Trial primary completion date: Nov 2014 --> Mar 2015
- |||||| cisplatin / Generic mfg.
Enrollment open: Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury (clinicaltrials.gov) - Dec 30, 2014
P2/3, N=182, Recruiting, Sponsor: Seoul National University Bundang Hospital
Trial primary completion date: Nov 2014 --> Mar 2015 Not yet recruiting --> Recruiting
- ||||| Gemiglo (gemigliptin) / Sanofi, LG Chem
Enrollment closed: Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin (clinicaltrials.gov) - Dec 30, 2014
P3, N=174, Active, not recruiting, Sponsor: LG Life Sciences
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- | Gemiglo (gemigliptin) / Sanofi, LG Chem
Trial completion, Trial primary completion date: Pharmacokinetic Drug Interaction Study Between Gemigliptin and Irbesartan After Oral Administration in Healthy Male Subjects (clinicaltrials.gov) - Dec 30, 2014
P1, N=30, Completed, Sponsor: LG Life Sciences
Not yet recruiting --> Active, not recruiting Enrolling by invitation --> Completed | Trial primary completion date: Dec 2013 --> Sep 2013
- ||||| ficlatuzumab (AV-299) / LG Chem
New P2 trial, Metastases: FOCAL: A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label (clinicaltrials.gov) - Dec 19, 2014
P2, N=86, Recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
- | Euvax B (recombinant hepatitis B vaccine) / LG Chem
New P4 trial: Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda (clinicaltrials.gov) - Dec 13, 2014
P4, N=132, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- | Besivo (besifovir) / Gilead, LG Chem, Ildong
New P1 trial: Bioequivalence Study to Compare the Pharmacokinetics of Besifovir in Healthy Adult Volunteers (clinicaltrials.gov) - Nov 25, 2014
P1, N=24, Not yet recruiting, Sponsor: IlDong Pharmaceutical Co Ltd
- |||| Shinbaro (GCSB-5) / GC Pharma, LG Chem
Trial primary completion date: Efficacy of Shinabro in Hand Osteoarthritis (clinicaltrials.gov) - Nov 24, 2014
P2/3, N=220, Recruiting, Sponsor: Seoul National University Hospital
Enrolling by invitation --> Completed | Trial primary completion date: Dec 2013 --> Sep 2013 Trial primary completion date: Aug 2014 --> Nov 2014
- ||| Gemiglo (gemigliptin) / Sanofi, LG Chem
Clinical: An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With Gemigliptin (clinicaltrials.gov) - Nov 14, 2014
P=N/A, N=5000, Recruiting, Sponsor: LG Life Sciences
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer (clinicaltrials.gov) - Nov 10, 2014
P2, N=7, Active, not recruiting, Sponsor: Emory University
Trial primary completion date: Aug 2014 --> Nov 2014 Recruiting --> Active, not recruiting | N=22 --> 7 | Trial primary completion date: Mar 2015 --> Jan 2016
- ficlatuzumab (AV-299) / LG Chem, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, New P1 trial, Metastases: Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Oct 28, 2014
P1, N=22, Not yet recruiting, Sponsor: Julie E. Bauman, MD, MPH
- ficlatuzumab (AV-299) / LG Chem
Biomarker, New P1 trial, Metastases: Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Oct 28, 2014
P1, N=24, Not yet recruiting, Sponsor: Julie E. Bauman, MD, MPH
- ||| Euforvac-Hib (diphtheria-tetanus-pertussis (whole cell)-hepatitis B-hemophilus influenzae type b) / LG Chem
Clinical: Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 Weeks (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=3000, Not yet recruiting, Sponsor: LG Life Sciences
- |||||||||| cisplatin / Generic mfg.
New P2/3 trial: Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury (clinicaltrials.gov) - Sep 28, 2014
P2/3, N=182, Not yet recruiting, Sponsor: Seoul National University Bundang Hospital
- ||| Adalimumab BS MA (adalimumab biosimilar) / Mochida, LG Chem
New P1 trial: Pharmacokinetics and Safety Study of LBAL in Healthy Subjects (clinicaltrials.gov) - Aug 1, 2014
P1, N=116, Not yet recruiting, Sponsor: LG Life Sciences
- | Eutropin Plus (somatropin SR) / LG Chem, Bioton
Enrollment open: Efficacy and Safety Study of Sr-hGH in Comparison With Daily hGH in ISS Patients (clinicaltrials.gov) - Jul 15, 2014
P2, N=45, Recruiting, Sponsor: LG Life Sciences
Recruiting --> Active, not recruiting | N=22 --> 7 | Trial primary completion date: Mar 2015 --> Jan 2016 Not yet recruiting --> Recruiting
- | Gemiglo (gemigliptin) / Sanofi, LG Chem
Trial completion: Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers (clinicaltrials.gov) - Jul 14, 2014
P1, N=28, Completed, Sponsor: LG Life Sciences
Not yet recruiting --> Recruiting Recruiting --> Completed
- Gemiglo (gemigliptin) / Sanofi, LG Chem
Clinical: Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=10, Not yet recruiting, Sponsor: Seoul National University Hospital
- ||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Enrollment closed, Metastases: A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas (clinicaltrials.gov) - Jun 26, 2014
P2, N=54, Active, not recruiting, Sponsor: Northwestern University
Recruiting --> Completed Recruiting --> Active, not recruiting
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial primary completion date, Metastases: RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 4, 2014
P1/2, N=50, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2013 --> Jun 2014